<DOC>
	<DOCNO>NCT00381212</DOCNO>
	<brief_summary>To Investigate safety immunologic activity AGS-004 , autologous HIV Immunotherapeutic , HIV-infected adult currently stable antiretroviral therapy ( ART ) durable viral suppression .</brief_summary>
	<brief_title>A Pilot Study Investigate Safety Immunologic Activity AGS-004 Autologous HIV Immunotherapeutic Agent .</brief_title>
	<detailed_description>Although HIV infection induce weak immune response , current HIV immunotherapy use consensus antigens show consistent clinical activity . The absence clinical activity associate inability raise cytotoxic T lymphocytes ( CTL ) HIV antigens failure induce T cell memory . While strong immune response may generate consensus antigen , responses offer antiviral protection patient 's individual viral burden . The infect virus ' antigen variability likely prevents establishment effective CD4+ T cell memory strong CD8+ T cell effector arm . We investigate induction CTL responses HIV-infected subject novel HIV immunotherapeutic agent ( AGS-004 ) effort overcome lack polyvalent specificity immune response autologous HIV antigens one primary reason failure HIV immunotherapy date . This pilot study investigate safety immunologic activity AGS-004 autologous HIV immunotherapeutic agent .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>HIV Seropositivity</mesh_term>
	<criteria>Men woman age 18 year , Documented HIV1 infection , Durable viral suppression ( ≤ 200 copy HIV1 RNA / mL ) first ART regimen least 12 week prior entry , Availability ≥ 2.5mL continuallyfrozen plasma start ART ( ≥30,000 copies/mL ) , CD4+ T cell count ≥200 cells/mm3 time preART sample , CD4+ T cell count ≥350 cells/mm3 obtain within 4 week study entry , No coinfection HBV HCV , No history lymph node irradiation dissection , No prior use HIV vaccine , No use hydroxyurea , No use systemic corticosteroid nonpermitted medication ,</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Immunotherapeutic injection</keyword>
</DOC>